Posted by Michael Wonder on 30 Aug 2023
Mitsubishi Tanabe Pharma Canada announces that company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in New Brunswick and Nova Scotia
29 August 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the New Brunswick Drug Plan formulary (special authorisation) and the Nova Scotia Formulary (exceptional status) for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
In addition to New Brunswick and Nova Scotia, Radicava oral suspension is also listed on the public drug plans in Ontario, Alberta, Québec and British Columbia.
